Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208312 | 0.84 | THRB (0.42) | THRBLMNA | |
| SCHEMBL10023016 | 0.81 | THRB (0.40) | THRBLMNA | |
| SCHEMBL11955576 | 0.81 | THRB (0.40) | THRBLMNA | |
| SCHEMBL9998684 | 0.81 | — | — | |
| SCHEMBL6565526 | 0.81 | DNM1 (0.52) | DNM1HTT | |
| SCHEMBL14962835 | 0.80 | — | — | |
| SCHEMBL15360264 | 0.80 | — | — | |
| SCHEMBL242883 | 0.79 | THRB (0.38) | THRBLMNA | |
| Hydrochloric Acid SCHEMBL9998583 | 0.78 | DNM1 (0.52) | DNM1THRBLMNA | |
| SCHEMBL26259006 | 0.78 | LMNA (0.38) | DNM1THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346700-A1 | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-1893584-A1 | DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Argenta Discovery Limited (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006136857-A1 | DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-5616581-A | BACTERICIDES | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| US-5504082-A | BACTERICIDE FOR HELICOBACTER, ANTIULCER AGENT, GASTRIC ACIDSUPPRESSOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0644191-A1 | PYRIDINE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | DNM1 847/4885THRB 4855/4885NOS3 2436/4885 |
| US-20230346700-A1 | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors | PDCD1LG2, PDCD1, CD274 | DNM1 996/4885THRB 4563/4885NOS3 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.